| Literature DB >> 24424211 |
Masanori Hiramitsu1, Yasuhito Shimada2, Junya Kuroyanagi3, Takashi Inoue4, Takao Katagiri4, Liqing Zang5, Yuhei Nishimura6, Norihiro Nishimura5, Toshio Tanaka6.
Abstract
Lemon (Citrus limon) contains various bioactive flavonoids, and prevents obesity and obesity-associated metabolic diseases. We focused on eriocitrin (eriodictyol 7-rutinoside), a powerful antioxidative flavonoid in lemon with lipid-lowering effects in a rat model of high-fat diet. To investigate the mechanism of action of eriocitrin, we conducted feeding experiments on zebrafish with diet-induced obesity. Oral administration of eriocitrin (32 mg/kg/day for 28 days) improved dyslipidaemia and decreased lipid droplets in the liver. DNA microarray analysis revealed that eriocitrin increased mRNA of mitochondrial biogenesis genes, such as mitochondria transcription factor, nuclear respiratory factor 1, cytochrome c oxidase subunit 4, and ATP synthase. In HepG2 cells, eriocitrin also induced the corresponding orthologues, and reduced lipid accumulation under conditions of lipid loading. Eriocitrin increased mitochondrial size and mtDNA content, which resulted in ATP production in HepG2 cells and zebrafish. In summary, dietary eriocitrin ameliorates diet-induced hepatic steatosis with activation of mitochondrial biogenesis.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24424211 PMCID: PMC3892443 DOI: 10.1038/srep03708
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Assessment of body weight and length, plasma TG, and hepatic steatosis in zebrafish overfed with eriocitrin.
(a) Average body weight; (b) average body length; and (c) BMI in each group during 4 weeks feeding. Each group contained 10 fish. All values are mean ± SEM. *P < 0.05, **P < 0.01 versus vehicle in the NF group. (d) Plasma TG levels in each group. Four weeks' administration of eriocitrin reduced plasma TG in the OF group. Values are mean ± SEM; n = 10, *P < 0.05. (e) Fasting blood glucose in each group. Values are mean ± SEM; n = 10. (f) Oil Red O staining of liver sections. Eriocitrin reduced the number of lipid droplets (red) compared with the OF group. Erio: eriocitrin.
Figure 2Analysis of DNA microarray data.
(a) Clustering analysis of DNA microarrays and (b) the average expression levels of clusters 7 and 10. (c) GSEA plots showed that expression of a mitochondrial gene module24 was more enriched in the OF + Erio group compared with the OF group.
Ontology analysis of genes with altered expression (clusters 7 and 10 in Fig. 2a) in eriocitrin administration
| Group | GO ID | GO Terms | genes | |
|---|---|---|---|---|
| ATP synthesis | GO:0006119 | Oxidative phosphorylation | atp5o, ndufs3, atp5d, ndufa4, atp5h, ndufa8, atp5l, ndufa6, atp6v1f, hcg_25371, ndufb5, ndufs6, atp5c1, ndufb6, ndufb2, ndufb8, ndufa2 | 1.84E-17 |
| GO:0042775 | Organelle ATP synthesis coupled electron transport | hcg_25371, ndufb5, ndufs6, ndufs3, ndufb6, ndufa4, ndufa8, ndufb2, ndufa6, ndufb8, ndufa2 | 1.30E-12 | |
| GO:0009145 | Purine nucleoside triphosphate biosynthetic process | atp5o, atp6v1f, atp5c1, atp5d, atp5j2, atp5h, nme1, atp5l | 1.10E-06 | |
| GO:0009108 | Coenzyme biosynthetic process | atp5o, atp5h, atp6v1f, atp5l, atp5c1, atp5d, atp5j2 | 0.000211878 | |
| Electron transport | GO:0006120 | Mitochondrial electron transport, NADH to ubiquinone | ndufb5, ndufs6, ndufs3, ndufb6, ndufa4, ndufa8, ndufb2, ndufa6, ndufb8, ndufa2 | 1.54E-12 |
| GO:0015985 | Energy coupled proton transport, down electrochemical gradient | atp5o, atp5h, atp6v1f, atp5l, atp5c1, atp5d | 1.39E-05 | |
| GO:0015992 | Proton transport | atp5o, atp5h, atp6v1f, atp5l, atp5c1, atp5d, atp5j2 | 2.07E-05 | |
| Other | GO:0006752 | Group transfer coenzyme metabolic process | atp5o, atp5h, atp6v1f, atp5l, atp5c1, atp5d, atp5j2 | 2.39E-05 |
| GO:0006414 | Translational elongation | rplp0, rplp1, eef1b2, rplp2 | 0.001341631 | |
| GO:0051289 | Protein homotetramerization | atpif1, pcbd1 | 0.006574703 |
qRT-PCR and DNA microarray results of eriocitrin administration
| qRT-PCR | DNA microarray | ||||
|---|---|---|---|---|---|
| Gene symbol | Gene ID | OF | OF + Erio | OF | OF + Erio |
| pparab | 557714 | 0.37 ± 0.05 | 1.18 ± 0.28 | nd | nd |
| acox1 | 449662 | 0.64 ± 0.12 | 1.24 ± 0.26 | 1.04 ± 0.21 | 1.02 ± 0.13 |
| acadm | 406283 | 0.73 ± 0.14 | 1.20 ± 0.14 | 0.98 ± 0.11 | 1.34 ± 0.13 |
| cox4i1 | 326975 | 0.59 ± 0.05 | 1.21 ± 0.13 | 1.01 ± 0.03 | 1.43 ± 0.15 |
| atp5j | 406599 | 0.72 ± 0.06 | 1.03 ± 0.12 | 1.06 ± 0.10 | 1.72 ± 0.16 |
| ppargc1a | 553418 | 0.27 ± 0.18 | 0.46 ± 0.11 | nd | nd |
| nrf1 | 64604 | 1.31 ± 0.32 | 3.43 ± 0.55 | 0.94 ± 0.16 | 1.04 ± 0.14 |
| tfam | 571106 | 0.42 ± 0.02 | 1.01 ± 0.12 | 0.78 ± 0.02 | 1.16 ± 0.10 |
All values are mean ± SEM; n = 4 or 5,
*P < 0.05,
**P < 0.01.
Figure 3qRT-PCR of genes related to lipid metabolism and mitochondrial functions, and eriocitrin reduced lipid accumulation in HepG2 cells.
To confirm the DNA microarray analyses, qRT-PCR was conducted. Genes related to lipid metabolism in zebrafish (a) and HepG2 cells (b). Genes related to mitochondrial biogenesis and respiratory function in zebrafish (c) and HepG2 cells (d). All values are means ± SEM; n = 5, *P < 0.05, **P < 0.01. (e) Oil Red O staining of HepG2. (f) Absorbance of Oil Red O during lipid accumulation. Eriocitrin reduced lipid accumulation in palmitate-stimulated HepG2. All values are means ± SEM; n = 8, *P < 0.05.
Figure 4Eriocitrin increased mitochondrial biogenesis and ATP production.
(a) Eriocitrin (10 μM) increased mitochondrial size (red) of HepG2 cells using MitoTracker Red CMXRos staining. Blue colour represents the nucleus (Hoechst 33342). (b) Quantitative analysis of mitochondrial staining. (c) Quantification of mtDNA was accomplished by calculating the ratio of CYTB to nuclear PK and expressing it as mtDNA copy number per cell. (d), (e) ATP quantification with eriocitrin administration. Upon 72 h administration of eriocitrin, there were increased intracellular ATP in HepG2 cells (d) and systemic ATP of 7 dpf zebrafish (e). All values are mean ± SEM; n = 8, *P < 0.05, **P < 0.01.
Prediction of eriocitrin mechanism using SNEA
| Gene set seed | Name | Total # of neighbours | # of measured neighbours | Measured neighbours | Median change | |
|---|---|---|---|---|---|---|
| Retinoid X receptor | 248 | 68 | APOA4, VEGFA, DDAH1, LCN2, FGFR1, CAV1, SCARB1, ABCC2, CYP27A1, FGB, HMOX1, MGP, ACOX1, CA2, NR1D1, ARG2, CYP8B1, VDR, ABCG5, LPL, CEBPA, PTPN6, RBP1, APOA1, CETP, DBI, FOS, MYOD1, ANGPTL3, THRB, BCL2, EGFR, BCL2L1, NDRG1, SLC2A2, ACADM, SLC27A2, ACLY, ACO1, PTH1R, CYP4A11, FABP1, GATA6, MEIS1, RXRG, COL1A2, PLIN2, SCP2, SLC27A1, CRABP1, CYBB, DUSP1, CCND1, ACACB, TRIB3, CYBA, ANGPTL4, ABCA1, NR1H4, NR1H3, HAND2, LDLR, SLC13A1, MAF, DCN, EGR1, RETN, SLC26A5 | −1.017 | 0.004 | |
| Sterol regulatory element binding transcription factor 1 | 134 | 50 | SLC2A2, CAV1, PTGDS, CEBPB, ABCA1, FABP1, CETP, ACSS2, HMGCS1, DBI, LPIN1, IRS2, PFKFB1, ACACB, ALDH1A2, INSIG1, VEGFA, PKLR, PDX1, SLC27A2, FDPS, HK2, RETN, ACLY, FADS2, ELOVL5, HMOX1, LPL, AR, HNF4A, LIPE, LIPC, CYP8B1, ACSL1, GNAI2, GPX3, PGD, CASP2, IDH1, HSD17B7, COL6A1, TRIB3, DHCR7, GPAM, SP1, HDC, LDLR, SCARB1, BAX, CEBPA | −1.055 | 0.005 | |
| STAT6 | Signal transducer and activator of transcription 6 | 119 | 20 | CAV1, BCL2, BAX, IGFBP1, COL1A2, BCL2L1, AICDA, AGT, IRS2, SOCS3, MUC5AC, IGF1, CDKN1B, MUC1, CLCA1, EGR1, MAF, PML, VCAM1, NFIL3 | −1.450 | 0.006 |
| CDX2 | Caudal type homeobox 2 | 64 | 11 | IRS2, HNF1A, CDH17, FABP2, HNF4A, VDR, ACAT2, SP1, HBEGF, LYPLA1, BCL2 | 1.328 | 0.007 |
| MAPK11 | Mitogen-activated protein kinase 11 | 36 | 11 | SCARB1, BAX, BCL2, HMOX1, VDR, CEBPD, PRDX1, CAV1, CEBPB, EGR1, CCND1 | 1.025 | 0.007 |
| Luteinizing hormone | - | 69 | 15 | LDLR, SCARB1, EGFR, AREG, CEBPD, RETN, C13orf15, KDR, IGFBP5, ANXA5, FLT1, IGFBP2, SGK1, PSEN1, CEBPB | −1.238 | 0.007 |
| NKX2-5 | NK2 homeobox 5 | 52 | 14 | CALR, TLL1, CTNNB1, GATA4, PITX2, ACTC1, DIO2, MEF2A, ACACB, T, PLOD1, MYOD1, HOPX, ACTA2 | −1.360 | 0.008 |
| HEY1 | Hairy/enhancer-of-split related with YRPW motif 1 | 23 | 11 | MDM2, RUNX2, ID1, ACTA2, KDR, GATA4, GATA6, MYF5, OCLN, AR, PRODH2 | −1.342 | 0.008 |
| Runt | Runt-related transcription factor | 50 | 9 | BCL2, C13orf15, LGALS3, CEBPD, TGFBR1, BTG2, SP1, IL7R, RUNX2 | −1.368 | 0.009 |